A Phase 1b/2 Open-label Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer With Expansion Cohorts in Patients With Non-small Cell Lung Cancer and Melanoma
Brief description of study
The purpose of this study is to determine the safety and tolerability of entinostat (an HDAC inhibitor) used in combination with pembrolizumab in patients with Non-small Cell Lung Cancer in subjects who have been previously treated with a PD-1 inhibitor as well as those who have never been treated with a PD-1 inhibitor.
Clinical Study Identifier: s16-00003
ClinicalTrials.gov Identifier: NCTs16-00003
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
